Well Referenced

Tag: mTOR

Long-lasting Geroprotection from Brief Rapamycin Treatment in Early Adulthood by Persistently Increased Intestinal Autophagy

This 2022 study published in Nature Aging demonstrates that a brief course of rapamycin treatment in early adulthood induces persistent activation of intestinal autophagy, leading to extended lifespan and improved gut barrier function in Drosophila and mice. Notably, the geroprotective effects were comparable to those seen with lifelong rapamycin administration,

Read More »
June 26, 2025 No Comments

Rapamycin and Ageing: When, for How Long, and How Much?

This 2014 review by Matt Kaeberlein evaluates critical variables in rapamycin use for aging interventions, including optimal dosing, treatment duration, and initiation timing. While rapamycin consistently extends lifespan in animal models, most studies employ a standard dose and continuous administration, potentially missing more effective strategies. Emerging evidence suggests intermittent or

Read More »
June 26, 2025 No Comments

Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan

This 2020 review explores how caloric restriction (CR) and caloric restriction mimetics (CRMs) enhance healthspan and lifespan through modulation of key nutrient-sensing pathways, including IGF-1, mTOR, and AMPK. CR has been associated with improved metabolic parameters, reduced inflammation, and extended lifespan in multiple species. CRMs—such as resveratrol, metformin, and rapamycin—aim

Read More »
June 26, 2025 No Comments

Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition

This 2006 review by Mikhail V. Blagosklonny introduces the “quasi-programmed” theory of aging, proposing that aging is an unintended continuation of developmental growth programs driven by pathways like mTOR. These hyperfunctional processes lead to age-related diseases and functional decline. The paper suggests that pharmacological inhibition of these pathways, particularly using

Read More »
June 26, 2025 No Comments

Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial

This randomized, single-blind, placebo-controlled trial evaluated the impact of metformin on longevity-associated pathways in 38 prediabetic individuals over two months. Participants received either metformin (1500 mg/day) or placebo. Metformin treatment led to significant improvements in metabolic parameters and insulin sensitivity. Notably, there was an increase in SIRT1 gene and protein

Read More »
June 26, 2025 No Comments

Glutamine, arginine, and leucine signaling in the intestine

The 2009 study “Glutamine, arginine, and leucine signaling in the intestine” (DOI: 10.1007/s00726-008-0225-4) investigates the roles of glutamine, arginine, and leucine in promoting intestinal health through various signaling pathways, including MAPK, mTOR, and cGMP. These amino acids stimulate cell migration, enhance mucosal integrity, and protect against oxidative stress and nutrient

Read More »
June 26, 2025 No Comments